Canadian PPE gets Unanimous Approval in the House of Commons
17 déc. 2021 18h27 HE | Canadian Association of PPE Manufacturers
CAMBRIDGE, Ontario, Dec. 17, 2021 (GLOBE NEWSWIRE) -- The Canadian Association of PPE Manufacturers (CAPPEM) would like to thank all House members for the unanimous vote of approval for the federal...
CAPPEM fully supports OHA directives to fight Omicron
16 déc. 2021 17h30 HE | Canadian Association of PPE Manufacturers
CAMBRIDGE, Ontario, Dec. 16, 2021 (GLOBE NEWSWIRE) -- With the high level of uncertainty over the effects of the newest COVID-19 variant Omicron, the Canadian Association of PPE Manufacturers...
Why are Canadian MPs wearing foreign masks
10 déc. 2021 13h59 HE | Canadian Association of PPE Manufacturers
CAMBRIDGE, Ontario, Dec. 10, 2021 (GLOBE NEWSWIRE) -- While Canadian companies struggle against product dumping and other unfair trade practices by China, why are Canadian Ministers of Parliament...
Screen Shot 2021-12-08 at 5.51.41 PM.png
CAPPEM supports Auditor General’s recommendations on Ontario PPE
08 déc. 2021 18h15 HE | Canadian Association of PPE Manufacturers
CAMBRIDGE, Ontario, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ontario fundamentally needs a robust, domestically produced supply of high quality Personal Protective Equipment (PPE), and The Canadian...
AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus
29 nov. 2021 14h57 HE | AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 2 TRIAL OF MASITINIB’S ANTIVIRAL ACTIVITY AGAINST THE SARS-CoV-2 (COVID-19) VIRUS Paris, 29 November, 2021, 8.45pm CET AB Science...
AB Science annonce le recrutement du premier patient dans l'étude de phase 2 évaluant l'activité antivirale du masitinib contre le virus SARS-CoV-2 (COVID-19)
29 nov. 2021 14h57 HE | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE RECRUTEMENT DU PREMIER PATIENT DANS l’ETUDE DE PHASE 2 EVALUANT L’ACTIVITE ANTIVIRALE DU MASITINIB CONTRE LE VIRUS SARS-CoV-2 (COVID-19) Paris, 29 novembre...
LSU ECE Professor Develops Contact-Tracing Mobile App
28 sept. 2021 14h00 HE | LSU College of Engineering
BATON ROUGE, La., Sept. 28, 2021 (GLOBE NEWSWIRE) -- LSU Electrical & Computer Engineering Professor Lu Peng and a team of ECE undergraduate and graduate students have developed a COVID-19...
Logo.jpg
Vystar Adds Fluid Energy Conversion Into Planned RxAir Spin-Off
20 sept. 2021 08h30 HE | Vystar Corp.
FEC patented technology has potential for applications in multiple industriesFEC to prioritize air and water purification R&D Worcester, MA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Vystar®...
Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
16 sept. 2021 07h30 HE | Exavir Therapeutics
With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...
Logo.jpg
Vystar Details Preliminary Plans for RxAir Spin Off as Shareholder Dividend
05 août 2021 08h00 HE | Vystar Corp.
Separation of RxAir® business offers pure-play investment opportunityVystar shareholders on the Record Date of January 5, 2022 to qualify for dividend of RxAir NewCo shares Worcester,...